Eli Lilly to build $3.5 billion injectable-medicine plant; Parkland board debates 10-year LERDA abatement

A presenter for the project told the Parkland School District board that Eli Lilly will invest “more than $3,500,000,000” to build an injectable medicines facility in the Lehigh Valley that is expected to employ about 850 full-time workers when complete. The company and regional economic-development officials framed the project as a decades-long anchor for the U.S. supply chain.

Lehigh Valley Economic Development Corporation representative Jamie Whalen said the district and region would benefit from workforce partnerships with Lehigh Carbon Community College and other training programs, and urged the board to partner on a 10-year Local Economic Revitalization Tax Assistance arrangement. “The LERDA is something that you know, it's not a it's not a giveaway,” Whalen said, adding the incentive was one factor that made the region competitive for the site.

District finance staff presented illustrative county assessments ranging from about $68 million to $105 million and described a phased 10-year abatement that would hold current base taxes while gradually phasing in taxes on newly assessed improvements once the plant is complete. Under the low-assessed-value scenario staff estimated a total abatement of roughly $8,000,000 over 10 years; under the high scenario they estimated about $12,500,000.

Board members repeatedly asked for additional historical assessment data and clarifications about timing. Several directors said they want the district’s budget seminar on May 1 to inform their decision before the item is scheduled for board consideration on May 12. Superintendent Matt Madsen and administrative staff said the estimates are illustrative and depend on the county’s eventual permanent assessment of the completed facility.